Clinical trial
A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies.
NCT05841771 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Phase 2 Study Evaluating Safety and Efficacy of Maintenance Therapy With Hypomethylating Agent and Venetoclax After Allogeneic Stem Cell Transplantation in Patients With f High-risk Myeloid Malignancies.
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 1, 2023
- Completion date
- December 31, 2025
- Enrollment
- 78 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hypomethylating agent, myeloid malignancy, venetoclax